Multiple Plasmodium falciparum targets involved in phospholipid metabolism and nucleic acid structures

This target profile represents a group of essential proteins and structures in Plasmodium falciparum that are simultaneously affected by bis-thiazolium and bis-quaternary ammonium compounds. The primary components include enzymes of the Kennedy pathway, such as choline/ethanolamine phosphotransferase and choline kinase, which are critical for the de novo synthesis of phosphatidylcholine required for rapid membrane biogenesis during the parasite's intraerythrocytic cycle. Additionally, these drugs interact with nucleic acid structures and associated proteins, potentially binding to the DNA minor groove or interfering with replication and transcription. This multi-target approach provides a potent mechanism to kill parasites rapidly and reduces the likelihood of developing single-point mutation resistance. Clinical candidates like Albitiazolium have targeted this profile to treat severe malaria, leveraging the parasite's heavy reliance on exogenous choline and its unique lipid metabolic pathways compared to human hosts.

Other names

Albitiazolium targetsBis-thiazolium targetsPlasmodium falciparum phospholipid and DNA targetsSAR97276 targets

Inhibition of choline/ethanolamine phosphotransferase (PfCEPT) and choline kinase (PfCK) to block phosphatidylcholine synthesis; binding to nucleic acid structures to disrupt DNA/RNA dynamics.